Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial

Background: The addition of trastuzumab (T) and lapatinib (L) to neoadjuvant chemotherapy increases the pathological complete response (pCR) rate in patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer. We investigated the efficacy of T or L with neoadjuvant che...

Descripción completa

Detalles Bibliográficos
Autores: Alba, Emilio, Albanell Mestres, Joan, Haba-Rodríguez, Juan de la, Barnadas, Agustí, Calvo, Lourdes, Sánchez-Rovira, Pedro, Ramos, Manuel, Rojo, Federico, Burgués, Octavio, Carrasco, Eva María, Caballero, Rosalía, Porras, Ignacio, Tibau, Ariadna, Cámara, Maria del Carmen, Lluch, Ana
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2014
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:10230/46396
Acceso en línea:http://hdl.handle.net/10230/46396
http://dx.doi.org/10.1038/bjc.2013.831
Access Level:acceso abierto
Palabra clave:HER2-positive breast cancer
Lapatinib
Neoadjuvant
Trastuzumab
Biomarkers
id ES_f09d912cbcf6074be75d1a8d6691bd2d
oai_identifier_str oai:recercat.cat:10230/46396
network_acronym_str ES
network_name_str España
repository_id_str
spelling Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trialAlba, EmilioAlbanell Mestres, JoanHaba-Rodríguez, Juan de laBarnadas, AgustíCalvo, LourdesSánchez-Rovira, PedroRamos, ManuelRojo, FedericoBurgués, OctavioCarrasco, Eva MaríaCaballero, RosalíaPorras, IgnacioTibau, AriadnaCámara, Maria del CarmenLluch, AnaHER2-positive breast cancerLapatinibNeoadjuvantTrastuzumabBiomarkersBackground: The addition of trastuzumab (T) and lapatinib (L) to neoadjuvant chemotherapy increases the pathological complete response (pCR) rate in patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer. We investigated the efficacy of T or L with neoadjuvant chemotherapy and specific efficacy biomarkers. Methods: Patients with stages I–III (including inflammatory) HER2-positive breast cancer were randomised to receive epirubicin (E) plus cyclophosphamide (C) × 4 cycles followed by docetaxel (D) plus either T (EC-DT) or L (EC-DL). End points included pCR (primary), clinical response, toxicity, and pCR-predictive biomarkers. Results: We randomised 102 patients to EC-DT (50) and EC-DL (52). Median age was 48, 56% were premenopausal and 58% had oestrogen receptor (ER)-positive tumours. Pathological complete response in breast was 52.1% (95% CI:38.0–66.2%) for EC-DT and 25.5% (95% CI:13.5–37.5%) for EC-DL (P=0.0065). Pathological complete response in breast and axilla was 47.9% for EC-DT and 23.5% for EC-DL (P=0.011). Grade 3–4 toxicity did not differ across treatments, except for diarrhoea (2% in EC-DT vs 13.5% in EC-DL, P=0.030). Multivariate analyses showed that treatment (P=0.036) and ER (P=0.014) were the only predictors of pCR in both groups. Conclusion: EC-DT exhibited higher efficacy and lower toxicity than EC-DL. Of the different biomarkers studied, only the absence of ER expression was associated with increased pCR.Nature Research202120212014info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttp://hdl.handle.net/10230/46396http://dx.doi.org/10.1038/bjc.2013.831reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésBritish Journal of Cancer. 2014 Mar 4;110(5):1139-47This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons AttributionNonCommercial-Share Alike 3.0 Unported License.https://creativecommons.org/licenses/by-nc-sa/3.0/info:eu-repo/semantics/openAccessoai:recercat.cat:10230/463962026-05-29T05:05:01Z
dc.title.none.fl_str_mv Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial
title Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial
spellingShingle Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial
Alba, Emilio
HER2-positive breast cancer
Lapatinib
Neoadjuvant
Trastuzumab
Biomarkers
title_short Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial
title_full Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial
title_fullStr Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial
title_full_unstemmed Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial
title_sort Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial
dc.creator.none.fl_str_mv Alba, Emilio
Albanell Mestres, Joan
Haba-Rodríguez, Juan de la
Barnadas, Agustí
Calvo, Lourdes
Sánchez-Rovira, Pedro
Ramos, Manuel
Rojo, Federico
Burgués, Octavio
Carrasco, Eva María
Caballero, Rosalía
Porras, Ignacio
Tibau, Ariadna
Cámara, Maria del Carmen
Lluch, Ana
author Alba, Emilio
author_facet Alba, Emilio
Albanell Mestres, Joan
Haba-Rodríguez, Juan de la
Barnadas, Agustí
Calvo, Lourdes
Sánchez-Rovira, Pedro
Ramos, Manuel
Rojo, Federico
Burgués, Octavio
Carrasco, Eva María
Caballero, Rosalía
Porras, Ignacio
Tibau, Ariadna
Cámara, Maria del Carmen
Lluch, Ana
author_role author
author2 Albanell Mestres, Joan
Haba-Rodríguez, Juan de la
Barnadas, Agustí
Calvo, Lourdes
Sánchez-Rovira, Pedro
Ramos, Manuel
Rojo, Federico
Burgués, Octavio
Carrasco, Eva María
Caballero, Rosalía
Porras, Ignacio
Tibau, Ariadna
Cámara, Maria del Carmen
Lluch, Ana
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv HER2-positive breast cancer
Lapatinib
Neoadjuvant
Trastuzumab
Biomarkers
topic HER2-positive breast cancer
Lapatinib
Neoadjuvant
Trastuzumab
Biomarkers
description Background: The addition of trastuzumab (T) and lapatinib (L) to neoadjuvant chemotherapy increases the pathological complete response (pCR) rate in patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer. We investigated the efficacy of T or L with neoadjuvant chemotherapy and specific efficacy biomarkers. Methods: Patients with stages I–III (including inflammatory) HER2-positive breast cancer were randomised to receive epirubicin (E) plus cyclophosphamide (C) × 4 cycles followed by docetaxel (D) plus either T (EC-DT) or L (EC-DL). End points included pCR (primary), clinical response, toxicity, and pCR-predictive biomarkers. Results: We randomised 102 patients to EC-DT (50) and EC-DL (52). Median age was 48, 56% were premenopausal and 58% had oestrogen receptor (ER)-positive tumours. Pathological complete response in breast was 52.1% (95% CI:38.0–66.2%) for EC-DT and 25.5% (95% CI:13.5–37.5%) for EC-DL (P=0.0065). Pathological complete response in breast and axilla was 47.9% for EC-DT and 23.5% for EC-DL (P=0.011). Grade 3–4 toxicity did not differ across treatments, except for diarrhoea (2% in EC-DT vs 13.5% in EC-DL, P=0.030). Multivariate analyses showed that treatment (P=0.036) and ER (P=0.014) were the only predictors of pCR in both groups. Conclusion: EC-DT exhibited higher efficacy and lower toxicity than EC-DL. Of the different biomarkers studied, only the absence of ER expression was associated with increased pCR.
publishDate 2014
dc.date.none.fl_str_mv 2014
2021
2021
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10230/46396
http://dx.doi.org/10.1038/bjc.2013.831
url http://hdl.handle.net/10230/46396
http://dx.doi.org/10.1038/bjc.2013.831
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv British Journal of Cancer. 2014 Mar 4;110(5):1139-47
dc.rights.none.fl_str_mv https://creativecommons.org/licenses/by-nc-sa/3.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/3.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Nature Research
publisher.none.fl_str_mv Nature Research
dc.source.none.fl_str_mv reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869423998554603520
score 15.811543

Similares en LA Referencia